The details that change the rehabilitation conversation
The early skin-risk window after spinal-cord injury, pain relief without more activity, brace–shoe mechanics, access to the next stage of care and a laser trial worth reading closely.
Half the sacral pressure injuries in a new spinal-cord injury cohort appeared within the first two weeks after trauma. The patients were still in acute care. That timing brings a familiar rehabilitation concern into sharp focus: preventing a complication cannot wait until the rest of recovery is ready.
Today's edition follows the details that can change a rehabilitation conversation: when skin risk emerges, what a pain intervention leaves unresolved, why a shoe belongs in a brace assessment, and whether a person actually receives the next stage of care. A new carpal-tunnel trial and a rheumatology guideline add treatment questions. Across these reports, a useful result starts with the right outcome and a clear understanding of who was studied.
All 88 registered sources and 15 study domains were checked. The scan retrieved 806 journal-article records plus one book record, with 107 article records newly retrieved against October 13. These are changes to capped discovery, including older work; they are not 107 new publications today. All 12 inaccessible registered sources were retried without recovery. Four main research reports were read in full, and four other research summaries use primary abstracts or previews. The actual BSR guideline summary, FDA communications and education descriptions were checked separately. Licensed chapters and course recordings were not reviewed.
The skin clock starts in acute care
Researchers at a Montréal Level I trauma centre followed 142 people with traumatic spinal-cord injury at L2 or above, in AIS grades A–C. Their primary outcome was the time from trauma to the first sacral pressure injury: damage around the lower-back bony prominence caused by sustained loading of vulnerable tissue.
Forty-five people, 31.7% of the cohort, developed a sacral injury. Half of those injuries occurred within the first two weeks. That is half of the injuries observed, not half of all 142 participants.
Motor-complete injury—AIS A or B—was associated with a higher hazard than motor-incomplete AIS C: adjusted hazard ratio 2.27, 95% confidence interval 1.07–4.83. A hazard ratio compares the rate at which an event occurs among people still free of it during follow-up; it does not mean that an individual's absolute probability is 2.27 times a known percentage.
The time pattern matters. Incidence was similar between severity groups during the first fourteen days, with the pressure-injury-free survival curves separating afterward. Early attention is relevant across this selected cohort; motor-complete injury also identifies a group requiring continued vigilance later in hospitalization. For patients and families, the practical conversation is when skin protection begins and how it continues through transfers between teams.
Clinical notes: timing, injury severity and what the study cannot prescribe
This was an observational cohort, not a trial of a turning schedule, support surface or prevention bundle. It cannot determine which intervention prevents how many injuries. Lower admission Braden scores had a borderline association with event timing: adjusted HR 0.90, 95% CI 0.81–1.00; p=0.0504. That result does not validate a new cutoff or establish that a score alone is adequate risk assessment.
The estimate for motor completeness is imprecise. Full adjustment variables, injury staging, prevention practices, discharge censoring and complete follow-up details were unavailable in the subscription preview. The cohort excludes AIS D and E and injuries below L2; its 31.7% is not a universal spinal-cord injury risk. Sponsorship was disclosed as Medline Industries. The report supports attention to timing and risk, while a treatment plan still requires condition-specific assessment.
Primary pressure-injury cohort abstract · Publisher preview and disclosures · DOI: 10.1038/s41393-026-01235-9
Less pain did not automatically mean more activity
A Swedish study followed people receiving spinal-cord stimulation for chronic neuropathic pain. Three months after implantation they began six months of individualized physiotherapist-led exercise, followed by twelve months of prescribed physical activity. The programme included strength, endurance and core training, with aerobic exercise adapted to clinical needs and preferences.
Thirty-five participants completed the nine- and twenty-one-month visits. In the available paired observations, Table III reports average neuropathic pain changes from baseline of −1.6 points at nine months, 95% CI −2.5 to −0.7, and −1.7 at twenty-one months, 95% CI −2.5 to −1.0, on a 0–10 scale. Perceived health on the EQ-5D visual scale improved by 14 points, with intervals of 4–23 and 7–22, respectively.
These are within-person changes from before implantation. The later visits did not show significant additional improvement compared with three months, when the exercise phase started. The design cannot establish whether exercise helped maintain earlier gains, added a benefit too small to detect, or contributed no benefit to the measured outcomes.
Accelerometer-measured moderate-to-vigorous activity remained low: medians of 15 minutes weekly at baseline, 11 at nine months and 12 at twenty-one months in the complete-follow-up group. No significant activity change was detected. Pain relief, perceived health, everyday function and activity intensity are related questions, but they should be measured separately. A patient may value a daily task that an activity monitor does not capture well.
Clinical notes: crossover, paired denominators and the harms table
The initial phase randomized 42 implanted participants to active or inactive stimulation, but 19 of 21 allocated to inactive stimulation crossed over. This long-term report analyzes a single group. It does not retain a randomized exercise comparator. Of 48 initially included people, 35 completed follow-up; available outcome denominators varied by visit. Some missing twenty-one-month questionnaires were replaced with twelve- or fifteen-month values. Mean paired changes therefore differ from subtracting the displayed group means. The paired Table III estimates and confidence intervals are used here; the abstract and narrative give different rounded changes and p-values.
Thirty-two of the 35 completers reported 84 adverse events during the two later phases: 31 judged related to stimulation, ten to supervised exercise, five to activity on prescription and 38 to other causes. Twenty-seven events were classified as CTCAE grade 3. These are event counts, not 27 different people or 27 confirmed device injuries. Implant removals, reoperations and lead revisions occurred. Without a comparison group, this report cannot estimate excess treatment risk.
Activity classification used a common estimated fitness value rather than individually measured maximal oxygen uptake. Hip accelerometry can miss aspects of cycling, water exercise, balance and strength work. The sample was small, selected after a successful stimulation test, and from one centre. The original primary endpoint concerned fifty-percent pain relief at three months, reported previously; the later analysis is not a new primary randomized success. The full main PDF, including Table III, Table IV and disclosures, was read and visually checked. The prior phase report, registry protocol and supplementary outcomes were not independently audited.
Primary stimulation and exercise follow-up · Publisher and complete main report · DOI: 10.2340/jrm.v58.46459
The shoe is part of the brace
An ankle-foot orthosis, or AFO, supports or constrains ankle movement. A new review examines what happens when footwear changes around that support. It includes fourteen studies with 204 participants: 108 healthy adults, 84 people after stroke and twelve with unilateral ankle weakness or pain. Most studies compared several conditions within the same person.
The most consistently studied adjustment was heel-sole differential: the height difference between the heel and forefoot. Increasing it in rigid-AFO users tended to incline the shank—the lower leg—forward and increase knee flexion during stance. A modification near the ankle can therefore affect the knee and hip. The direction of that change may help one gait pattern and work against another.
The review reports directions of biomechanical effects rather than a pooled treatment difference with a confidence interval. It does not establish one ideal heel height, a universal shoe prescription, fewer falls or a specified gain in community walking. Its practical implication is to assess the AFO and usual footwear together, and to reassess the combination when shoes change.
Clinical notes: the three rockers and the limits of a mechanical explanation
During the heel rocker, the forefoot lowers after initial contact. During the ankle rocker, the body progresses over the planted foot. During the forefoot rocker, the heel rises toward toe-off. Footwear shape and AFO stiffness affect the timing of these transitions and the lever arms of the ground-reaction force. The review distinguishes biomechanical theory from observed study results; neither alone establishes a patient-important benefit.
The search was updated in May 2026. Screening and quality scoring involved two reviewers, but extraction was performed by one author. Ten papers were rated good and four fair using a modified checklist; none reported successful blinding. Device details often had to be inferred from photographs. Four of five forefoot-rocker studies came from the same institution, and the range of diagnoses was narrow. Findings from healthy adults or predominantly rigid AFOs cannot simply be extended to children, all neurological diagnoses or compliant devices. Individual source studies, review appendices and figure images were not separately appraised.
Primary review record · Complete review, methods and tables · DOI: 10.2196/93423
A prescription gap is a care question
A Veterans Health Administration study examined 16,157 people undergoing major lower-limb amputation in 2010–2022. Its outcomes were a qualifying prosthesis prescription and an advanced-component prescription within twelve months. “Any prosthesis” excluded people receiving only preparatory devices or accessories, a definition that matters when interpreting who counted as untreated.
Compared with White Veterans, Black Veterans were 5.7 percentage points less likely to receive a qualifying prescription, 95% confidence limits 4.0–7.5; Hispanic Veterans were 5.6 points less likely, limits 2.4–8.8. Differences for advanced components were 1.7 and 3.0 percentage points, respectively. A percentage-point gap compares percentages directly; it is different from a relative percentage reduction.
The researchers decomposed these disparities using measured demographic, clinical, facility and amputation factors. Facility factors accounted statistically for 58.2% of the White–Black gap in any prescription. They also modeled hypothetical changes in care, including targeted investment in facilities serving more Black Veterans. One modeled scenario narrowed that gap by 1.86 percentage points, or 32.5%. This was an estimate under assumptions, not the observed result of a quality-improvement trial.
For patients, the implication is to make the evaluation and next step explicit: what is the functional goal, what is being prescribed, what clinical issues require attention, and who will follow the decision? A group disparity does not explain an individual decision, but it identifies a service pattern worth examining.
Clinical notes: “explained” does not mean justified or causally corrected
Statistical decomposition identifies associations with measured distributions. It does not prove that moving a patient, removing a diagnosis or changing a facility label produces the modeled effect. The prescriptive analysis used machine learning and cross-fitting, but its causal interpretation still depends on assumptions about confounding, measurement and how an intervention would operate.
The cohort was 98.3% male and excluded several neurological conditions likely to preclude prosthesis use, prior major amputations, deaths during the index procedure and some racial groups with insufficient sample size. Records lacked detailed mobility, healing, preferences and prescriber factors; devices obtained outside VHA were unobserved. An advanced component in the first year is not appropriate for every patient. These results do not establish that every absent prescription was an avoidable denial or that higher technology improves every person's outcome. Main methods, narrative results, displayed tables and limitations were read; supplements and detailed identification assumptions were not independently audited.
Primary Veterans prosthesis-prescription cohort · Publisher main report · DOI: 10.1097/MLR.0000000000002385
Discharge is a handoff, not an outcome
Another study followed 23,036 community-dwelling older adults who received inpatient rehabilitation for traumatic brain injury in 2020–2022. It linked Medicare records with discharge measures of self-care and mobility, then looked for therapy received within ninety days.
Home-health occupational therapy was recorded for 52% and home-health physical therapy for 67%. Outpatient rates were 15% for occupational therapy and 27% for physical therapy. These are service-specific proportions that may overlap; they should not be added to calculate a percentage receiving any rehabilitation.
Worse mobility predicted home-health PT use, but did not predict outpatient PT use. Nonclinical factors—including rurality, ethnicity, age, marital status and Medicaid eligibility in different analyses—were associated with access. The abstract does not provide adjusted effect sizes or intervals for those comparisons, so their magnitude is not reproduced here.
A useful discharge conversation extends beyond a referral: which service will provide the care, whether an appointment or home visit is arranged, what barriers remain, and what happens if the plan does not begin. This study measures utilization; it does not establish that a referral was made, why care was absent, or whether a particular service improved function.
Clinical notes: need, utilization and unmet need
Clinical need was operationalized through Section GG performance scores, rather than a comprehensive individual therapy assessment. Modified Poisson models examined receipt of each service with clinical and nonclinical covariates. Claims cannot fully describe preferences, caregiver availability, authorization barriers, treatment quality or a decision that therapy was not indicated. Full eligibility and missing-data methods were unavailable. The findings motivate better transitions without assigning a single cause to every care gap.
Primary post-TBI community-rehabilitation cohort · DOI: 10.1007/s11606-026-10844-2
A short-term laser signal with a dose question
A single-centre Pakistani trial randomized 69 adults aged 20–40 with mild, subacute carpal-tunnel syndrome, confirmed electrically, to higher-intensity laser plus physiotherapy, lower-level laser plus the same physiotherapy, or sham laser plus physiotherapy. There were 23 participants per group and eighteen sessions over six weeks. All completed the immediate post-treatment assessments.
Pain and the Boston Carpal Tunnel Questionnaire were described as co-primary outcomes in the main report. Mean pain scores changed from 6.8 to 1.9 with the higher-intensity regimen, 6.9 to 2.8 with the lower-level regimen and 6.7 to 4.5 with sham. The calculated unadjusted post-treatment difference for higher-intensity versus sham is −2.6 points; it is not a reported baseline-adjusted mean effect. The outcome table reports significant pairwise differences but gives no confidence intervals for these comparisons.
Mean functional-status scores were 1.5, 1.9 and 2.6 after treatment, respectively; lower is better. Nerve-conduction, grip and ultrasound measures also improved. The study supports a short-term signal for these particular regimens. It does not show lasting recovery, reduced recurrence, avoidance of surgery or benefit in older adults with more severe disease.
Clinical notes: multiple parameters, retrospective registration and reproducibility
The regimens differed in wavelength, power, spot size and fluence, so intensity alone was not isolated. Allocation concealment and assessor blinding were described; therapists were unblinded, and the success of participant blinding was not tested. Pairwise comparisons used Bonferroni correction, but registration occurred in March 2025 after recruitment began in August 2024, limiting confirmation of prospective outcomes and analyses. No adverse events were reported during this small, brief trial.
The low-level regimen is reported as 0.05 W, ten stationary treatment points and 300 J total energy within a ten-minute session. A simple consistency check gives 0.05 J/s × 600 s = 30 J over ten minutes for a single continuously emitting probe. The published description therefore needs clarification before its optical dose can be reproduced. This calculation does not establish which parameter was delivered or invalidate every clinical observation. Power and spot sizes were not independently measured. The article acknowledges dose-verification limits; this edition does not offer a treatment recipe.
The authors compare within-group improvements with clinical-importance thresholds. For judging the add-on, the relevant comparison is between groups, with uncertainty. Mechanisms involving inflammation, mitochondria or nerve repair were hypothesized rather than directly tested. Tables II and III and main methods/results/limitations were read; remaining table details, figures, the registry and cited threshold studies were not independently audited.
Primary carpal-tunnel laser trial · Complete main report · DOI: 10.1007/s10103-026-05070-5
Polymyalgia care includes the cost of steroid exposure
The British Society for Rheumatology now lists its 2026 polymyalgia rheumatica guideline as current. The official summary recommends bone protection unless contraindicated, early reassessment of response, discussion of rheumatology referral to consider methotrexate, and specialist consideration of steroid-sparing therapy for relapse, toxicity risk, inadequate response or inability to taper. Continuous education and support run through the pathway.
This is a guideline update, not a new drug trial. Its PubMed journal issue date is October 1; it was newly identified in today's focused search. A recommendation's strength and evidence certainty cannot be reconstructed from a flowchart, and the full guideline remained inaccessible after retries.
Clinical notes: urgent diagnostic review and the access boundary
The actual summary lists atypical features and diagnostic uncertainty as reasons for rheumatology review. Features concerning for giant-cell arteritis—including new headache, scalp tenderness, jaw claudication, visual loss or double vision—require immediate specialist review. The taper is individualized; a patient should not change glucocorticoids from this summary alone. The one-page official pathway was read and visually inspected. Detailed recommendation grades, supporting trials and monitoring schedules were not appraised.
Primary BSR guideline record · Official current guideline and summary sheet · DOI: 10.1093/rheumatology/keag502
Two findings to keep in their proper frame
An ultrasound AI study evaluated 79 adults using 3,017 clips and 15,600 frames. Its endpoint was anatomical segmentation against expert annotations, with a Dice-overlap threshold of 0.50 defining a successful segmentation. High reported agreement does not establish diagnostic accuracy for disease, safe independent procedures or improved patient outcomes. Thousands of frames are repeated observations, not thousands of independent patients. Full validation and training-separation details were unavailable. Primary AI segmentation abstract.
A double-blind trial of intranasal neural stem cells in 24 people with early-onset Parkinson's disease did not meet its primary six-month motor-complications endpoint: difference 0.42, 95% CI −4.29 to +5.13. Later motor and imaging signals were exploratory; 137 adverse events and six serious events were reported, without sufficient abstract detail to assign causality or compare rates. This remains investigational evidence, not an established rehabilitation treatment. Primary stem-cell trial abstract.
The safety desk: an older warning worth recognizing
The FDA's September 1, 2026 Injectafer communication concerns symptomatic low phosphate after ferric carboxymaltose. Weakness, fatigue and muscle or bone pain can resemble the anemia being treated; chronic severe hypophosphatemia can cause bone softening and fractures. Patients should promptly report new or worsening symptoms. Clinicians should correct pre-existing low phosphate, monitor people at risk, and check phosphate before repeat treatment when risk is present or a repeat course occurs within three months. Severe or persistent cases warrant treatment review. This is established safety guidance, not an October 14 announcement. Actual FDA drug safety communication.
The Medline kit notice and Philips Lumify alert were reread. The former's October 13 Class I classification leaves its affected products and recommendations unchanged; the latter remains the October 9 alert. See yesterday's safety desk for the reviewed details and direct notices. Complete inventory attachments and device images were not appraised today.
Today, October 14, noon–1 p.m. Eastern, the FDA lists a virtual panel on Bayesian clinical-trial design and its January 2026 draft guidance. Its description covers prior information, success criteria, missing data and reporting; the preparatory video and live panel were not reviewed. The linked guidance remains a draft, not for implementation. The AAPM&R October 19 journal club, 7:30–8:30 p.m. Central, lists spinal-cord autonomic and knee-PRP papers. Its course page states no credit offered. These are opportunities to study, not evidence that the sessions were attended or that this magazine grants credit. FDA event description · AAPM&R course description.
Test the interpretation
A patient improves after a stimulator implant, then receives an exercise programme. Later pain scores remain better than before implantation, with no significant improvement from the visit immediately before exercise. The long-term study has no concurrent control. Which statement best fits the evidence?
- Exercise caused the entire improvement from baseline.
- The programme has been proved ineffective for every activity and patient.
- Improvement persisted during the programme, but its added or maintenance effect cannot be determined.
- The original device allocation makes the exercise comparison randomized.
Reveal answer and reasoning
C. Time sequence and baseline improvement do not isolate the effect of an add-on. The full report's crossover and single-arm follow-up do not supply a randomized exercise comparison. A nonsignificant later difference also does not establish universal ineffectiveness. Patient goals, activity measurement, missing data and harms remain relevant to interpretation.
Words worth keeping
- Hazard ratio
- A comparison of event rates during follow-up among people who have not yet had the event; it is not an absolute risk.
- Confidence interval
- A range expressing statistical uncertainty under the analysis assumptions. It does not account for every source of bias.
- Paired change
- A change calculated within the same participants. With missing observations, it can differ from subtracting two displayed group averages.
- Motor-complete injury
- In this cohort, the AIS A and B categories, compared with motor-incomplete AIS C.
- Heel-sole differential
- The height difference between a shoe's heel and forefoot, which can affect an AFO user's lower-leg alignment.
- Percentage point
- The direct difference between percentages: 58% minus 52% is six percentage points.
- Modeled intervention
- A predicted outcome under a hypothetical change and stated assumptions, rather than a treatment actually tested.
- Fluence
- Energy delivered per unit area, commonly expressed in joules per square centimetre.
- Co-primary outcomes
- More than one main outcome, requiring clear prospective definitions and an appropriate analysis plan.
- Hypophosphatemia
- Low phosphate in the blood; serious or prolonged cases can affect muscles and bones.
References & the coverage record
- Timing of sacral pressure injury development during acute care after traumatic spinal cord injury: a prospective study of 142 patients. Spinal cord · PMID 42869926 · DOI 10.1038/s41393-026-01235-9
- Long-term effects of spinal cord stimulation combined with a physiotherapist-led exercise programme and physical activity on prescription for chronic neuropathic pain. Journal of rehabilitation medicine · PMID 42870412 · DOI 10.2340/jrm.v58.46459
- Ankle-Foot Orthosis and Footwear Interactions in Adult Healthy and Patient Populations: Systematic Review of Biomechanical Outcomes. JMIR rehabilitation and assistive technologies · PMID 42869424 · DOI 10.2196/93423
- Quantifying and Addressing Racial and Ethnic Disparities in Lower-Limb Prosthesis Prescriptions Among US Veterans. Medical care · PMID 42868516 · DOI 10.1097/MLR.0000000000002385
- Gaps in Access to Home and Community-Based Services Following Inpatient Rehabilitation for Traumatic Brain Injury in Older Adults. Journal of general internal medicine · PMID 42870188 · DOI 10.1007/s11606-026-10844-2
- Clinical outcomes of low versus high intensity laser therapy in patients with subacute carpal tunnel syndrome: A randomized, single-blinded, controlled trial. Lasers in medical science · PMID 42870113 · DOI 10.1007/s10103-026-05070-5
- The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica. Rheumatology (Oxford, England) · PMID 42869454 · DOI 10.1093/rheumatology/keag502
- Artificial Intelligence Segmentation In Musculoskeletal Ultrasound: A Novel Study Across Five Joints Using Expert Ground Truth. American journal of physical medicine & rehabilitation · PMID 42870329 · DOI 10.1097/PHM.0000000000003181
- Intranasal human neural stem cell therapy in early-onset Parkinson's disease with motor complications: A randomized, double-blind, placebo-controlled trial. Cell transplantation · PMID 42868224 · DOI 10.1177/09636897261494929
Eight research reports were appraised: a prospective pressure-injury cohort, a single-arm stimulation/exercise follow-up with crossover in its initial allocation, a biomechanical systematic review, two retrospective care-access cohorts, a randomized laser trial, a cross-sectional AI segmentation study and a small randomized stem-cell trial. The complete main stimulation PDF, Tables III–IV and disclosures were read; methods and outcome/harms tables were visually checked on rendered pages. Its prior phase paper, registry protocol and supplements were not independently appraised. The AFO review main methods, displayed tables, results, discussion and limitations were read through verified web access after direct fetches returned empty content; individual included studies, appendices and figure images were not audited. Main Veterans prosthesis methods, displayed tables, narrative results and limitations were read; supplements and identification assumptions were not independently audited. The laser trial main full text and primary Tables II–III were recovered on publisher retry and appraised; remaining detailed tables, figures, registry and cited clinical thresholds were not independently audited. Reported low-power dosing is internally unclear; a dimensional consistency calculation is labeled separately. Pressure-injury and TBI care-access summaries use their primary abstracts and subscription previews; complete reports remained unavailable. AI segmentation and Parkinson stem-cell summaries use primary abstracts only after publisher access retries. The BSR 2026 polymyalgia guideline primary abstract and actual official one-page summary were read and its pathway visually inspected; full guideline access failed, so detailed grading and supporting trials were not appraised. Its PubMed issue date is October 1 rather than a confirmed October 14 publication date. Actual FDA Injectafer, Medline kit and Lumify communications were read with their original/status dates distinguished. Complete device inventory attachments and images were not reviewed. Actual FDA Bayesian event/draft-status and AAPM&R October journal-club descriptions were checked, not videos, live sessions, linked study full texts or the complete Bayesian draft. NICE stroke recommendations were retrieved but not used for clinical claims. All 88 registered-source status records, 15 domain results, 107 newly retrieved article titles/dates and 38 landing-page comparisons were inspected; no new links were detected within the capped landing snapshots. All 12 inaccessible registered sources were retried without recovery. The scan contains 806 journal-article records and one book identifier. A focused 24-record search was screened, with older, repeated, preclinical and unrelated material kept separate. Metadata discovery is capped, all domain queries truncated, and does not establish exhaustive full-content coverage or no updates at inaccessible sources. Licensed chapters, audio and course recordings were not reviewed. No physician review is recorded. This edition grants no CME and the study question is original educational material.
The discovery window was 2026/09/14–2026/10/14. A journal index check can miss work not yet indexed. A retrieved landing page does not verify every linked publication, paid course, podcast or textbook chapter. Candidate counts are discovery records, not validated practice changes.
See every registered source and its status → · Download this edition’s machine-readable coverage record
Educational, not medical advice. Discuss treatment choices with your clinician. Sources and evidence evolve; each dated edition preserves what was checked for that issue.